First Tracks Biotherapeutics, Inc. (TRAX)
Market Closed
30 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary 
XDUS $
47. 78
+5.91
+14.1151%
$
1.24B Market Cap
- P/E Ratio
- Div Yield
970,058 Volume
- Eps
$ 41.87
Previous Close Want to track TRAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
TRAX closed today higher at $47.78, an increase of 14.1151% from yesterday's close, completing a monthly increase of 201.4511% or $31.93. Over the past 12 months, TRAX stock gained 138.9%.
TRAX is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away.
Seekingalpha | 2 months ago
First Tracks Biotherapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Kevin Kroskey True Wealth Design LLC | 4 | $71.12 | $147.48 | $76.36 | 107.37% |
 Curtis Burkholder Bare Financial Services, Inc | 70 | $1,244.6 | $2,486.4 | $1,241.8 | 99.78% |
| WJ William Jones TEMA ETFs LLC | 30,907 | $549,526.46 | $1.15M | $602,068.36 | 109.56% |
First Tracks Biotherapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anupam Rama JP Morgan | 534.82 | $9,992.14 | $22,382.36 | $12,390.22 | 124% |
| EB Emily Bodnar HC Wainwright & Co. | 127.21 | $2,412.29 | $5,323.89 | $2,911.6 | 120.7% |
First Tracks Biotherapeutics, Inc. (TRAX) FAQ
What is the stock price today?
The current price is $47.78.
On which exchange is it traded?
First Tracks Biotherapeutics, Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is TRAX.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.24B.
Has First Tracks Biotherapeutics, Inc. ever had a stock split?
No, there has never been a stock split.
First Tracks Biotherapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Daniel R. Faga CEO | NASDAQ (NGS) Exchange | 337185102 CUSIP |
| US Country | 104 Employees | - Last Dividend | - Last Split | - IPO Date |
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Contact Information
Address: 10770 Wateridge Circle
Phone: 858 362 6295
Website: https://www.firsttracksbio.com
